Bladder Treatments Prescribed by UK Doctors

Overactive bladder (OAB) is a symptom complex defined by the International Continence Society as urinary urgency, usually with frequency (more than 8 voids per day) and nocturia (waking to void once or more per night), with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology.

OAB affects 12-17% of UK adults, with prevalence rising with age — 30% of those over 65 and 40% of those over 75 are affected.

It impairs quality of life comparably to diabetes mellitus and is associated with increased falls (2-fold risk in elderly patients rushing to the toilet), depression, social isolation, and sleep disruption.

Pathophysiology is multifactorial:

• Detrusor overactivity: involuntary contractions of the bladder muscle during filling, mediated by muscarinic M3 receptor activation
• Urothelial dysfunction: abnormal sensory signalling from the bladder lining via ATP and acetylcholine release
• Central nervous system changes: reduced cortical inhibition of the micturition reflex, particularly in neurological conditions (MS, Parkinson's, stroke)
• Age-related changes: reduced bladder compliance, decreased functional capacity, and altered circadian ADH secretion (contributing to nocturnal polyuria)

OAB subtypes:

• OAB wet: urgency with urge incontinence (accounts for approximately one-third of OAB patients)
• OAB dry: urgency and frequency without incontinence (two-thirds of patients)

Differential diagnosis must exclude:

• Urinary tract infection (MSU dipstick and culture)
• Bladder cancer: painless haematuria in patients over 45 warrants urgent 2-week pathway cystoscopy referral
• Bladder outlet obstruction (BPH in men): post-void residual ultrasound above 100 mL suggests incomplete emptying
• Diabetes mellitus and diabetes insipidus (osmotic diuresis)
• Excessive fluid intake (above 2.5 litres daily)
• Medications: diuretics, lithium, SSRIs, cholinesterase inhibitors

A 3-day bladder diary recording fluid intake, void volumes, frequency, urgency episodes, and incontinence episodes is the single most useful diagnostic tool, providing objective data to guide treatment selection.

Pharmacotherapy for OAB follows NICE CG171 guidelines and is initiated when behavioural interventions alone provide insufficient symptom control.

Two drug classes are first-line: antimuscarinics and beta-3 adrenoceptor agonists.

Antimuscarinic agents block muscarinic M3 receptors on the detrusor muscle, reducing involuntary contractions and increasing functional bladder capacity.

Solifenacin 5-10 mg daily is the most widely prescribed antimuscarinic for OAB. It has relative M3 selectivity, producing better efficacy-to-side-effect ratio than non-selective agents.

The STAR trial (solifenacin vs tolterodine) demonstrated superior urgency reduction and fewer pad changes. Solifenacin 5 mg reduces urgency episodes by 52%, frequency by 2.

2 voids/day, and incontinence episodes by 55%.

Tolterodine 4 mg modified-release daily is an older alternative with reasonable efficacy but higher dry mouth rates (18-24%).

Oxybutynin 5 mg two to three times daily is highly effective but limited by anticholinergic side effects (dry mouth 60-70%, constipation 15%, blurred vision 5%). Oxybutynin patches (3.

9 mg, changed twice weekly) deliver medication transdermally, reducing first-pass metabolism and GI side effects.

Mirabegron 50 mg daily is a beta-3 adrenoceptor agonist — a fundamentally different mechanism.

It relaxes the detrusor during filling by activating beta-3 receptors, increasing bladder capacity without muscarinic blockade.

The SCORPIO and ARIES trials showed efficacy comparable to antimuscarinics with significantly fewer anticholinergic side effects.

Mirabegron advantages:

• No dry mouth (reported in only 3% vs 8-24% with antimuscarinics)
• No constipation
• No cognitive impairment (critical advantage in elderly patients)
• Can be combined with solifenacin when monotherapy is insufficient (SYNERGY trial)

Prescribing considerations:

• NICE recommends offering a choice of antimuscarinic or mirabegron, discussing side-effect profiles to guide preference
• Trial for at least 4-8 weeks before assessing efficacy
• If one antimuscarinic is not tolerated, switch to an alternative or to mirabegron rather than abandoning pharmacotherapy
• Antimuscarinics should be used with extreme caution in elderly patients (over 65) due to cognitive decline risk — the MHRA has highlighted the cumulative anticholinergic burden

Anticholinergic medications are among the most commonly prescribed drug classes in the UK, and their cumulative burden has become a major patient safety concern, particularly in older adults.

The anticholinergic burden refers to the total anticholinergic effect from all medications a patient takes.

Beyond OAB drugs, common contributors include tricyclic antidepressants (amitriptyline), first-generation antihistamines (chlorphenamine), antipsychotics, and antispasmodics (hyoscine).

Tools such as the ACB (Anticholinergic Cognitive Burden) scale and DART (Drug Burden Index) quantify this total load.

Cognitive effects: A landmark study published in JAMA Internal Medicine (2015) involving 3,434 participants found that cumulative anticholinergic use over 10 years was associated with a 54% increased risk of dementia.

The risk was dose-dependent — higher total exposure correlated with greater risk.

This has led to NICE and the MHRA advising against anticholinergic OAB drugs in patients with pre-existing cognitive impairment or dementia, and extreme caution in those over 65.

Peripheral anticholinergic side effects and their clinical significance:

• Dry mouth (20-60% depending on agent): increases dental caries risk, impairs nutrition, and reduces medication compliance
• Constipation (10-20%): can worsen existing GI conditions and compound opioid effects
• Blurred vision (5-10%): particularly troublesome for elderly patients, increasing fall risk
• Urinary retention (paradoxical in OAB treatment): check post-void residual if new hesitancy develops
• Tachycardia: avoid in uncontrolled cardiac arrhythmias

Mirabegron as the preferred agent in elderly patients:

• No anticholinergic cognitive risk
• Main caution: can raise blood pressure by 1-2 mmHg — monitor BP at baseline and 4-8 weeks. Contraindicated in severe uncontrolled hypertension (above 180/110)
• QT prolongation: caution with concurrent QT-prolonging drugs

Monitoring recommendations:

• Review anticholinergic burden at least annually using a validated scale
• Check post-void residual volume if voiding symptoms develop on antimuscarinic therapy
• Assess cognitive function (MoCA or similar) in patients over 65 before starting antimuscarinics
• Consider deprescribing antimuscarinics and switching to mirabegron if cognitive concerns emerge
• Regular reassessment of ongoing pharmacotherapy need — OAB symptoms fluctuate and may improve with sustained behavioural training

Behavioural interventions are NICE first-line for OAB and produce durable improvements that persist beyond the treatment period.

A supervised 6-week bladder training programme reduces urgency and frequency by 50-80% in motivated patients.

Bladder retraining targets the learned association between urgency and immediate voiding. The protocol involves:

• Voiding by the clock at progressively longer intervals (start at your current average interval, e.g., every 1.5 hours)
• Increase the interval by 15-30 minutes each week, aiming for 3-4 hourly voiding
• When urgency strikes between scheduled voids, use urgency suppression techniques:
• Sit down and press firmly on the perineum (stimulates pudendal nerve inhibition of detrusor)
• Perform 5-6 rapid pelvic floor contractions ("quick flicks") to reflexively inhibit detrusor activity
• Distraction: count backwards from 100 by 7s, or perform a mental task requiring concentration
• Breathe slowly and calmly — anxiety amplifies urgency perception

Pelvic floor muscle training (PFMT) strengthens the striated muscles that provide external urethral sphincter support.

A Cochrane review confirms PFMT reduces incontinence episodes by 50-70% in women with stress or mixed incontinence.

For OAB specifically, the voluntary pelvic floor contraction inhibits detrusor activity via a spinal reflex arc.

PFMT protocol: 8-12 near-maximal contractions, held for 6-8 seconds each, performed 3 times daily for at least 3 months.

Fluid management:

• Total daily intake of 1.5-2.0 litres is optimal — neither restriction nor excess helps
• Reduce evening fluid intake after 6 PM to minimise nocturia
• Limit bladder irritants: caffeine (reduces bladder capacity by 15-20%), alcohol, carbonated drinks, artificial sweeteners, and acidic fruit juices
• A 3-day bladder diary objectively demonstrates the link between fluid intake patterns and symptom severity

Weight management: Each unit increase in BMI raises OAB risk by 3-5%. Losing 5-10% of body weight reduces incontinence episodes by 50-60% in overweight women, as demonstrated in the PRIDE trial.

Constipation management: A loaded rectum compresses the bladder, worsening urgency and frequency. Adequate fibre (30 g/day), hydration, and regular bowel habits reduce OAB symptoms.

Chronic constipation should be actively treated alongside bladder symptoms.